NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic …

SHELTON, CT, December 9, 2025 (EZ Newswire) -- NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) today reported that ...